B. Braun Medical Inc.  

Bethlehem,  PA 
United States
http://www.bbraunusa.com.

• Booth: 1540

Profile

B. Braun Medical Inc. will present its expanding portfolio of regional anesthesia and pain control products designed to improve efficiency and reduce contamination in booth #1540 at the American Society of Anesthesiologists (ASA) meeting.

The market leader in regional anesthesia, B. Braun will present products designed to address the continued need for enhanced needle visualization and guidance, organize the anesthesia work space in an operating room, and reduce medication errors.

B. Braun develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician, and environmental safety. B. Braun Medical is headquartered in Bethlehem, PA, and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap®, and CAPS®.

Globally, the B. Braun Group of Companies employs more than 61,000 employees in more than 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners, and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.bbraunusa.com.

 Press Releases

• Drugs Are Back in B. Braun Regional Anesthesia Trays (Oct 17, 2019)

  BETHLEHEM, PA – October 17, 2019 — B. Braun Medical Inc. (B.Braun) announced today it has made significant investments to help ensure a stable drug supply to reduce the risk of tray backorders associated with market drug shortages.

  “As the U.S leader in Regional Anesthesia,¹ patient care is our top priority. We are committed to providing you and your patients an uninterrupted supply of Regional Anesthesia procedural trays,” said Pete McGregor, Director of Marketing for Pain Control. “B. Braun continues to add products to our robust therapy portfolio that address post-operative pain and help reduce the use of opioids,” McGregor continued.  

  Adequate pain management is crucial for medical and surgical procedures during the perioperative period. In order to manage pain - while reducing opioid consumption, including their associated side effects - multimodal pain management strategies have become an important part of the peri-operative care process. Replacing general anesthetic gas and opioid approaches in favor of combinations of regional and local methods, such as Neuraxial anesthesia (spinal / epidural approach) and regional nerve blocks (single shot or continuous infusion) are key.

  As the U.S market leader in Regional Anesthesia,¹ B.Braun advocates and educates for the appropriate use of Regional Anesthesia and acute Pain Management to help manage the cost and complexity of healthcare delivery, while achieving improved patient and facility outcomes.

  About B. Braun

  B. Braun Medical Inc. (B.Braun) a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. Other key product areas include nutrition, pharmacy admixture, ostomy and wound care, and dialysis. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap^® and CAPS^®.

  Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise^® philosophy, B.Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit bbraunusa.com.

  ¹ 2018Q2 All Regional Anesthesia Products – Total Market HC & OPM Dollars (GHX, IQVIA [MDSA] & B. Braun Data On File)

• B. Braun Showcases Market Leading Regional Anesthesia Portfolio at ASA 2019 (Oct 17, 2019)

  BETHLEHEM, PA – October 17, 2019 — B. Braun Medical Inc. (B.Braun), the U.S. market leader in Regional Anesthesia¹, will showcase its robust Regional Anesthesia portfolio at this year’s Anesthesiology Annual Meeting (ASA) from October 19-23 in Orlando, Florida.

  In a simulated hospital setting at booth #1540, B.Braun will showcase the following products:

  • < > Point-of-Care Ultrasound System: The ultrasound system is designed to support the needs in regional anesthesia at the point of care. The system is designed to offer an intuitive user interface and image quality for needle targeting and positioning, as well as ergonomic features such as an articulating arm. Xperius' imaging complements B.Braun's regional block portfolio. Xperius is the first product resulting from a strategic alliance between < > Ultra 360^® Nerve Block Needles: Stimuplex Ultra 360 needles feature B.Braun’s echogenic 360º X-pattern. The ‘X’ is a unique shape, which when combined with a clear coating, reflects more ultrasound waves back to the probe than previous designs.^² These needles are designed to provide visibility without compromising puncture characteristics.

    Drugs Are Back in Regional Anesthesia Trays: As the U.S. leader in Regional Anesthesia¹, we have invested heavily since 2015 in initiatives to help ensure a stable drug supply and reduce the risk of tray backorders associated with drug shortages.

  • < >(chloroprocaine hydrochloride): B.Braun launched its first FDA- approved local anesthetic, Clorotekal^® (chloroprocaine hydrochloride*). Clorotekal is indicated for intrathecal injection for the production of subarachnoid block (spinal anesthesia) in adults undergoing spinal anesthesia. It is available in 50 mg/ 5 mL glass ampules. See below for indications, contraindications, and Full Prescribing Information. Full Prescribing Information and healthcare provider information for Clorotekal (chloroprocaine hydrochloride) at www.clorotekalusa.com.

    *Clorotekal is a registered trademark of Sintetica S.A. and is manufactured for B. Braun Medical Inc.

    About B. Braun

    B. Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. Other key product areas include nutrition, pharmacy admixture, ostomy and wound care, and dialysis. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap^® and CAPS^®.

    Globally, the B. Braun Group of Companies employs more than 64,000 employees in 64 countries. Guided by its Sharing Expertise^® philosophy, B.Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit bbraunusa.com.

    ¹ 2018Q2 All Regional Anesthesia Products – Total Market HC & OPM Dollars (GHX, IQVIA [MDSA] & B. Braun Data On File)

     ² Internal testing: ETRs NPAK-A8TP7B

 Products